Clinical bottom line
Oral iron chelation therapy represents an important option for managing iron overload in primary care, particularly for patients with secondary iron accumulation due to transfusions or chronic conditions. Emerging oral agents may improve adherence compared to parenteral chelators, potentially reducing iron-mediated organ damage. However, evidence remains limited regarding long-term outcomes in diverse primary care populations, and therapy requires careful monitoring for efficacy and toxicity. Clinicians should weigh benefits against risks such as optic neuropathy and liver fibrosis, tailoring treatment to individual patient profiles and coordinating with specialists as needed.
What the evidence shows
Iron overload, whether hereditary or secondary to repeated transfusions or chronic diseases, can cause significant tissue damage, including liver fibrosis, cardiac dysfunction, and endocrine abnormalities (Bridges et al., 2001). Chelation therapy aims to reduce excess iron and mitigate these complications. Traditionally, parenteral agents like deferoxamine have been standard but pose adherence challenges due to administration complexity.
Oral iron chelators, such as deferasirox and deferiprone, have been developed to improve patient convenience and adherence. Goodman et al. (2006) highlighted that newly approved oral chelators may enhance adherence in transfusion-dependent patients, a critical factor for effective iron reduction. Adams et al. (2011) discussed that while chelation primarily reduces iron burden, it may also slow progression of liver fibrosis, a key morbidity driver in iron overload states.
However, iron chelation is not without risks. Melachuri Samyuktha et al. (2024) recently reported optic neuropathy as a potential adverse effect of both iron overload and chelation therapy, underscoring the need for vigilant monitoring. Barton et al. (2007) reviewed chelation therapy's benefits and limitations, emphasizing individualized treatment plans based on iron burden, organ involvement, and patient tolerance.
Beyond classical indications, Meyer et al. (2006) explored iron chelation's theoretical role in infections like HIV and tuberculosis co-infection, where iron availability influences pathogen growth. Although intriguing, such applications remain experimental and not yet relevant to routine primary care.
Caveats and uncertainty
Most evidence on oral iron chelation derives from specialized hematology or gastroenterology settings, with limited data on primary care populations managing secondary iron overload from diverse causes. Long-term safety and efficacy in broader, less selected cohorts remain incompletely characterized.
Adverse effects such as renal impairment, gastrointestinal symptoms, and rare but serious optic neuropathy require careful risk-benefit assessment. The optimal timing to initiate chelation, target iron levels, and monitoring intervals are not standardized for primary care and often rely on specialist guidance.
Additionally, variability in patient adherence, comorbidities, and concurrent medications complicate therapy management. The impact of newer oral agents on clinical outcomes beyond iron metrics, such as quality of life or organ function preservation, warrants further study.
How this may change practice
Primary care clinicians should consider oral iron chelation therapy as a feasible option for patients with documented iron overload, especially those who struggle with parenteral regimens. Early identification of iron excess through appropriate screening and collaboration with hematology or hepatology specialists is essential.
Education on adherence importance, potential adverse effects, and regular monitoring of iron indices and organ function can optimize outcomes. Awareness of rare but serious complications like optic neuropathy should prompt timely ophthalmologic evaluation if symptoms arise.
Future integration of oral chelators into primary care may enhance management of iron overload beyond hereditary hemochromatosis, including secondary causes such as transfusion-dependent anemias. However, clinicians should remain cautious, individualizing therapy and consulting specialists for complex cases.